Blood Collection Tube for Liquid Biopsy Market

Blood Collection Tube for Liquid Biopsy Market Analysis and Forecast by Fact.MR

• The global market for blood collection tubes designed for liquid biopsy applications is estimated at USD 188.4 million in 2026 and is forecast to expand at a CAGR of 19.6% to reach USD 1,128.0 million by 2036.
• The market covers cell-free DNA stabilization tubes, circulating tumor cell collection tubes, standard blood collection tubes adapted for molecular analysis, and specialized multi-analyte stabilization tubes.
• Growth is shaped by the expanding clinical adoption of liquid biopsy in oncology diagnostics, the rising number of FDA-cleared liquid biopsy assays, growing utilization in non-invasive prenatal testing, and increasing pharmaceutical investment in companion diagnostic development.

Summary of Blood Collection Tube for Liquid Biopsy Market

• Market Snapshot
  • In 2025, the global Blood Collection Tube for Liquid Biopsy Market was valued at approximately USD 157.5 million.
  • The market is estimated to reach USD 188.4 million in 2026 and is projected to attain USD 1128.0 million by 2036.
  • The blood collection tube for liquid biopsy market is likely to expand at a CAGR of 19.6% during the forecast period.
  • The market is anticipated to create an absolute dollar opportunity of USD 939.6 million between 2026 and 2036.
  • Cell-free DNA blood collection tubes account for 44.8% of the product type share in 2026.
  • China (26.5%) and India (24.5%) are the key growth markets during the forecast period.
• Demand and Growth Drivers
  • Expanding clinical adoption of liquid biopsy for cancer detection, treatment monitoring, and minimal residual disease assessment is creating growing demand for specialized blood collection tubes that preserve cell-free DNA integrity.
  • Rising number of FDA-cleared and CE-marked liquid biopsy assays requiring validated pre-analytical workflows is increasing procurement of cfDNA-stabilizing collection tubes across reference laboratories.
  • Growing utilization of non-invasive prenatal testing (NIPT) for genetic screening is expanding the addressable market for cell-free DNA collection tubes beyond oncology.
  • Increasing pharmaceutical investment in companion diagnostics and biomarker-driven clinical trials is driving demand for standardized blood collection formats that ensure sample quality across multi-site studies.
  • Expanding molecular diagnostic laboratory infrastructure in China, India, and Brazil is creating first-time procurement demand for liquid biopsy-compatible collection systems.
• Product and Segment View
  • Cell-free DNA blood collection tubes account for 44.8% of the product type segment in 2026, supported by the dominant role of cfDNA analysis in oncology liquid biopsy workflows.
  • Oncology diagnostics account for 48.6% of the application segment in 2026, with lung cancer, breast cancer, and colorectal cancer detection acting as the primary demand channels.
  • Hospitals account for 42.3% of the end use segment in 2026, driven by growing in-house molecular diagnostic capabilities in hospital pathology laboratories.
• Key segmentation includes:
  • Product Type: Cell-Free DNA Blood Collection Tubes, Circulating Tumor Cell Collection Tubes, Standard Blood Collection Tubes, Specialized Liquid Biopsy Tubes
  • Application: Oncology Diagnostics, Treatment Monitoring, Minimal Residual Disease Detection, Prenatal and Genetic Testing, Research Applications
  • End Use: Hospitals, Diagnostic Laboratories, Cancer Research Institutes, Pharmaceutical and Biotechnology Companies
  • Technology: Cell-Free DNA Preservation Technology, Cell Stabilization Technology, Multi-Omics Stabilization Technology
  • Sample Type: Plasma Samples, Whole Blood Samples, Serum Samples
  • Distribution Channel: Direct Sales, Distributors, Online Channels
• These systems enable:
  • Stabilization of cell-free DNA at draw-time concentrations for reliable downstream molecular analysis.
  • Preservation of circulating tumor cells for enumeration and genomic characterization.
  • Standardized pre-analytical workflows that support multi-site clinical trials and reference laboratory testing.
• Geography and Competitive Outlook
  • North America remains a leading regional market, supported by the highest concentration of liquid biopsy assay developers, reference laboratories, and clinical trial activity globally.
  • Europe shows steady demand shaped by expanding molecular diagnostic infrastructure and growing adoption of liquid biopsy in clinical oncology practice.
  • Asia Pacific is the fastest-growing region, with China and India leading through expanding molecular diagnostic laboratory buildout and growing adoption of cancer screening programs.
  • China (26.5%) and India (24.5%) are the key growth markets, while the USA, Germany, and UK maintain strong clinical adoption patterns.
  • Key players include Streck, Inc., Qiagen N.V., Roche Holding AG, PreAnalytiX GmbH, and Greiner Bio-One International GmbH.
• Analyst Opinion
  • Shambhu Nath Jha, Principal Consultant at Fact.MR, says 'The blood collection tube for liquid biopsy market is at an inflection point. As liquid biopsy moves from research to clinical standard of care, the pre-analytical supply chain is becoming a critical differentiator. Companies that establish their tubes as the validated collection format within FDA-cleared assay workflows will build strong switching costs. The opportunity is not in the tube itself but in becoming the embedded pre-analytical standard across oncology diagnostics, companion diagnostics, and multi-cancer early detection programs.'

Key Growth Drivers, Constraints, and Opportunities

Key Factors Driving Growth

• Expanding clinical adoption of liquid biopsy across oncology diagnostics is creating sustained demand for cfDNA-stabilizing blood collection tubes validated within cleared assay workflows.
• Growing number of multi-cancer early detection programs and population-level screening initiatives are increasing per-capita tube consumption in developed markets.
• Rising pharmaceutical investment in companion diagnostics and biomarker-driven clinical trials is expanding tube procurement through contract research organizations and central laboratories.

Key Market Constraints

• High per-tube cost of specialized cfDNA collection tubes compared to standard EDTA tubes limits adoption in price-sensitive and high-volume screening settings.
• Limited standardization across liquid biopsy pre-analytical workflows creates fragmentation in tube selection and procurement across laboratories using different assay platforms.
• Regulatory complexity around validated pre-analytical components adds compliance burden for tube manufacturers seeking to establish their products within cleared diagnostic workflows.

Key Opportunity Areas

• Multi-cancer early detection programs represent a large volume growth opportunity as population-level screening expands tube consumption from specialist oncology to primary care settings.
• Development of multi-analyte stabilization tubes that preserve cfDNA, RNA, proteins, and exosomes in a single tube format is creating premium product tiers for multi-omics liquid biopsy applications.
• Expansion of molecular diagnostic laboratory infrastructure in China, India, and Brazil is creating first-time procurement demand for liquid biopsy-compatible collection systems at scale.

Segment-wise Analysis of the Blood Collection Tube for Liquid Biopsy Market

• Cell-free DNA blood collection tubes hold 44.8% of the product type segment in 2026, supported by the dominant role of cfDNA analysis in clinical liquid biopsy applications and validated integration with FDA-cleared assay workflows.
• Oncology diagnostics represents 48.6% of the application segment in 2026, with lung cancer, breast cancer, and colorectal cancer detection and monitoring acting as the primary demand channels.
• Specialized liquid biopsy tubes including multi-analyte and RNA stabilization formats are growing faster in percentage terms, with adoption rising as multi-omics approaches expand beyond cfDNA-only analysis.

The blood collection tube for liquid biopsy market is segmented by product type, application, end use, technology, sample type, distribution channel, and region. By product type, the market covers cell-free DNA tubes, CTC collection tubes, standard adapted tubes, and specialized multi-analyte tubes. By application, coverage includes oncology diagnostics, treatment monitoring, minimal residual disease detection, prenatal testing, and research. Cell-free DNA tubes lead by value due to their validated role in clinical oncology, while multi-analyte tubes are expected to drive the next phase of growth.

Which Product Type Segment Dominates the Blood Collection Tube for Liquid Biopsy Market?

Cell-free DNA blood collection tubes are expected to account for 44.8% of the product type segment in 2026, supported by their established role as the standard pre-analytical component for liquid biopsy workflows in clinical oncology. cfDNA tubes from Streck, Roche (PreAnalytiX), and Qiagen have been validated within multiple FDA-cleared and CE-marked assay systems, creating strong procurement linkages with reference laboratory workflows.

Circulating tumor cell collection tubes and specialized multi-analyte stabilization tubes represent growing segments, with adoption rising as liquid biopsy applications expand beyond cfDNA analysis into CTC enumeration, exosome characterization, and multi-omics profiling. Multi-analyte tubes are especially relevant for pharmaceutical biomarker studies where preservation of multiple analyte classes in a single draw is commercially valuable.

Which Application Segment Dominates the Blood Collection Tube for Liquid Biopsy Market?

Oncology diagnostics are expected to account for 48.6% of the application segment in 2026. Demand is shaped by the expanding use of liquid biopsy for cancer detection, therapy response monitoring, and minimal residual disease assessment across lung, breast, colorectal, and prostate cancer indications. Each cleared oncology liquid biopsy assay creates a recurring tube procurement stream.

Treatment monitoring and minimal residual disease detection follow as significant applications, with longitudinal patient monitoring creating repeat collection tube demand over extended treatment periods. Prenatal and genetic testing also contributes meaningfully, with NIPT programs generating high-volume tube consumption in reproductive health laboratories.

Which End Use Segment Dominates the Blood Collection Tube for Liquid Biopsy Market?

Hospitals account for 42.3% of the end use segment in 2026, driven by growing in-house molecular diagnostic capabilities in hospital oncology and pathology departments. Hospital procurement is increasingly linked to assay platform selection, with tube purchasing bundled into laboratory supply contracts.

Diagnostic laboratories, including reference laboratories and molecular diagnostic labs, represent the second largest end use channel. These laboratories process the highest volumes of liquid biopsy tests and maintain validated procurement relationships with specific tube manufacturers based on assay validation requirements.

Which Product Trend is Shaping the Next Phase of Growth in the Blood Collection Tube for Liquid Biopsy Market?

Multi-analyte stabilization tubes are not yet the largest product segment, but they are emerging as the fastest-growing capability in the market. Their adoption is projected to rise as liquid biopsy applications expand from cfDNA-only analysis toward integrated multi-omics profiling that requires simultaneous preservation of DNA, RNA, proteins, and extracellular vesicles in a single blood draw.

The shift toward multi-analyte tubes reflects a broader change in how liquid biopsy is used in both clinical and pharmaceutical settings. Researchers and clinicians increasingly need comprehensive molecular profiles from a single sample, and pharmaceutical companies running biomarker-intensive clinical trials require tubes that preserve multiple analyte classes without separate collection protocols. Companies that develop validated multi-analyte stabilization chemistry with broad assay compatibility are positioned to capture this transition.

Regional Outlook Across Key Markets

• China leads growth at 26.5%, supported by rapid molecular diagnostic laboratory expansion, growing adoption of liquid biopsy in hospital oncology departments, and government investment in cancer screening programs.
• India follows at 24.5%, driven by growing diagnostic laboratory infrastructure, rising cancer diagnosis volumes, and expanding access to molecular testing in urban hospital networks.
• Germany at 22.5% benefits from strong clinical adoption of liquid biopsy, established reference laboratory networks, and supportive reimbursement for molecular oncology diagnostics.
• The U.S. at 18.6% reflects a mature market with growth driven by expanding multi-cancer early detection programs, new assay clearances, and growing companion diagnostic utilization.

CAGR Table

Source: Fact MR (FMR) analysis, based on proprietary forecasting model and primary research.

Market Outlook for Blood Collection Tubes for Liquid Biopsy in the United States

The U.S. blood collection tube for liquid biopsy market is projected to grow at a CAGR of 18.6% through 2036. Demand is shaped by the highest concentration of cleared liquid biopsy assays globally, expanding multi-cancer early detection programs, and strong pharmaceutical clinical trial activity.

• Cleared assay expansion creates validated procurement pathways for cfDNA collection tubes.
• Multi-cancer early detection programs are scaling tube consumption toward population-level volumes.
• Pharmaceutical companion diagnostic investment sustains research-grade tube demand.

China Blood Collection Tube for Liquid Biopsy Market Growth Assessment

The China blood collection tube for liquid biopsy market is projected to grow at a CAGR of 26.5% through 2036, making it the fastest-growing country in the study. Growth is supported by rapid molecular diagnostic laboratory buildout, government cancer screening investments, and growing domestic liquid biopsy assay development.

• Molecular diagnostic laboratory expansion drives first-time specialized tube procurement.
• Government cancer screening programs increase liquid biopsy utilization at scale.
• Domestic assay developers are creating local demand for validated collection tubes.

Blood Collection Tube for Liquid Biopsy Demand Trends in India

The India blood collection tube for liquid biopsy market is projected to grow at a CAGR of 24.5% through 2036. Demand is shaped by growing diagnostic laboratory infrastructure, rising cancer diagnosis volumes, and expanding molecular testing access in urban hospital networks.

• Diagnostic laboratory growth is creating procurement demand for specialized collection tubes.
• Rising cancer diagnosis volumes expand liquid biopsy test utilization.
• Urban hospital investment in molecular diagnostics supports tube adoption.

Germany Blood Collection Tube for Liquid Biopsy Market Demand Analysis

The Germany blood collection tube for liquid biopsy market is projected to grow at a CAGR of 22.5% through 2036. Demand is supported by established reference laboratory networks, clinical adoption of liquid biopsy in oncology, and supportive reimbursement for molecular diagnostics.

• Established reference laboratories maintain structured procurement for validated tubes.
• Clinical oncology adoption of liquid biopsy sustains diagnostic tube demand.
• Reimbursement support for molecular testing improves liquid biopsy utilization rates.

Competitive Benchmarking and Company Positioning

Blood Collection Tube for Liquid Biopsy Market Analysis By Company

• Streck, Inc., Qiagen N.V., and Roche Holding AG (through PreAnalytiX) hold strong positions in the global blood collection tube for liquid biopsy market through validated cfDNA stabilization products, integration with cleared assay workflows, and established procurement relationships with reference laboratories.
• Norgen Biotek Corp., Greiner Bio-One International GmbH, and Biocept, Inc. compete through specialized product offerings, multi-analyte stabilization chemistry, and partnerships with assay developers in oncology and prenatal testing.
• Assay validation partnerships and regulatory integration create significant switching costs, as laboratories are unlikely to change collection tubes once a specific format is validated within their cleared diagnostic workflows.

The competitive landscape is moderately concentrated, with Streck maintaining the largest share through its Cell-Free DNA BCT platform, which has become a de facto standard in many liquid biopsy workflows. Competition is shaped by validation status within cleared assays, preservation performance, sample stability duration, and pricing in volume procurement.

Strategic priorities include expanding validation partnerships with assay developers, developing multi-analyte stabilization formats, extending sample stability windows, and building direct procurement relationships with reference laboratories and pharmaceutical central laboratories.

Key Companies in the Blood Collection Tube for Liquid Biopsy Market

• Streck, Inc., Qiagen N.V., and Roche Holding AG (through PreAnalytiX) are among the leading players globally, with Streck maintaining the largest share through its established Cell-Free DNA BCT platform.
• Norgen Biotek Corp., Greiner Bio-One International GmbH, and Biocept, Inc. hold positions in specialized segments including multi-analyte stabilization and CTC collection.
• Geneseeq Technology Inc., Apostle Inc., Exact Sciences Corp, and other companies compete through focused product offerings and regional distribution strength.

Recent Industry Developments

• Streck, Inc. / Product Platform Expansion / cfDNA BCT Validation (2025)
  • Streck continued to expand validation partnerships for its Cell-Free DNA BCT platform, supporting integration with newly cleared liquid biopsy assays for oncology diagnostics and multi-cancer early detection applications.
• Roche Holding AG / Liquid Biopsy Ecosystem Expansion (2025)
  • Roche expanded its liquid biopsy ecosystem through continued development of its cell-free DNA collection tube portfolio in partnership with Qiagen through the PreAnalytiX joint venture, supporting standardized pre-analytical workflows for companion diagnostic programs.
• Exact Sciences Corp / Multi-Cancer Early Detection Program Expansion (2025)
  • Exact Sciences expanded its multi-cancer early detection testing program, generating growing procurement demand for validated cfDNA blood collection tubes across clinical sites and reference laboratories.

Leading Companies Shaping the Blood Collection Tube for Liquid Biopsy Market

• Streck, Inc.
• Qiagen N.V.
• Roche Holding AG
• Biocept, Inc.
• PreAnalytiX GmbH (BD and Qiagen JV)
• Norgen Biotek Corp.
• Greiner Bio-One International GmbH
• Geneseeq Technology Inc.
• Apostle Inc.
• Exact Sciences Corp

Sources and Research References

• Streck, Inc. Cell-Free DNA BCT product portfolio and validation data.
• Qiagen N.V. PAXgene Blood ccfDNA Tube product updates.
• Roche Holding AG. Liquid biopsy collection tube portfolio through PreAnalytiX.
• U.S. Food and Drug Administration (FDA). Liquid biopsy assay clearance records.
• National Cancer Institute (NCI). Cancer screening and liquid biopsy clinical trial data.
• Primary interviews with tube manufacturers, reference laboratory directors, assay developers, clinical pathologists, and pharmaceutical biomarker teams.
• This bibliography is provided for reader reference and is not exhaustive. The full report contains the complete reference list and detailed citations.

Key Questions This Report Addresses

• What is the current and future size of the blood collection tube for liquid biopsy market?
• How fast is the market expected to grow between 2026 and 2036?
• Which product type is likely to lead the market by 2026?
• Which application segment is expected to account for the highest demand by 2026?
• What factors are driving demand for liquid biopsy blood collection tubes globally?
• How is multi-cancer early detection expanding the addressable market?
• Why are China and India the fastest-growing markets?
• How do assay validation partnerships influence tube procurement?
• Which countries are projected to show the fastest growth through 2036?
• Who are the key companies active in the market?
• What role does pre-analytical standardization play in market growth?
• How does Fact.MR estimate and validate the market forecast?

Blood Collection Tube for Liquid Biopsy Market Definition

The blood collection tube for liquid biopsy market covers specialized blood collection devices designed to stabilize cell-free DNA, circulating tumor cells, RNA, exosomes, and other analytes in whole blood samples for downstream molecular analysis in oncology diagnostics, prenatal testing, and biomarker research.

Blood Collection Tube for Liquid Biopsy Market Inclusions

• The scope covers global and regional market size and forecasts for 2026 to 2036 across product type, application, end use, technology, sample type, distribution channel, and region.
• It includes regional demand analysis based on liquid biopsy assay adoption, molecular diagnostic laboratory density, clinical trial activity, and cancer screening program expansion.
• The report includes pricing and cost analysis across cfDNA tubes, CTC collection tubes, and specialized stabilization tubes, including per-tube costs and volume procurement economics.
• It covers technology trends, market drivers and constraints, and the competitive landscape, including product portfolios, assay validation partnerships, and distribution strategies of leading players.

Blood Collection Tube for Liquid Biopsy Market Exclusions

• The scope excludes general-purpose blood collection tubes (EDTA, serum, heparin) used for routine hematology and chemistry testing without liquid biopsy-specific stabilization chemistry.
• It excludes liquid biopsy assay kits, sequencing platforms, and molecular diagnostic instruments sold without blood collection tube components.
• The report excludes tissue biopsy consumables, sample transport containers, and laboratory processing equipment.
• It also excludes point-of-care blood collection devices and capillary blood sampling systems not validated for liquid biopsy workflows.

Blood Collection Tube for Liquid Biopsy Market Research Methodology

• The methodology combines secondary research, primary interviews, and forecast modelling.
• It draws on 100+ secondary sources and benchmarks 40+ company product portfolios.
• Market sizing covers 30+ countries through a demand-side model supported by top-down validation.
• Key inputs include liquid biopsy assay adoption rates, molecular diagnostic laboratory counts, clinical trial volumes, and cancer screening program budgets.
• The model cross-checks demand with tube shipment data, pricing trends, and assay validation partnerships.
• Primary validation includes 20+ interviews across tube manufacturers, laboratory procurement teams, assay developers, and clinical pathologists.
• Final estimates go through assay-volume checks, procurement-pattern review, and sensitivity testing.